- Policy
- 14 generics for Albendazole, were already approved this year
- by Lee, Tak-Sun Aug 12, 2020 06:00am
- Albendazole is on the rise this year. Albendazole is an anthelmintic ingredient that began to obtain domestic approval in the early 1980s, and only four products were approved from 2017 to 2019. However, as other effects other than the approval of Albendazole became known through social media, new licensed generics have rapidly increased t
- Company
- Sayana and Gonal-F shortage may last longer than expected
- by Aug 12, 2020 05:59am
- Shortages in various drug products are reportedly caused by manufacturing facility changes and unstable supply of pharmaceutical substances. According to pharmaceutical distribution industry sources on Aug. 10, Pfizer Pharmaceutical Korea, Merck Korea, Dalim Biotech and other companies have recently informed of shortages in some products
- Policy
- Genexine, conducts clinical trials of 'GX-I7'
- by Lee, Tak-Sun Aug 12, 2020 05:59am
- Interleukin-7 anticancer drug candidate, being developed by Genexine, will conduct a clinical trial in Korea in patients with COVID-19. The MFDS announced on the 7th that it has approved a phase I clinical trial plan for 'GX-I7', a domestically developed COVID-19 treatment. As a result, there have been a total of 15 clinical trials (13 tr
- Policy
- Administrative court rules against Lilly on Forsteo pricing
- by Lee, Tak-Sun Aug 11, 2020 06:03am
- The administrative court rejected Lilly Korea’s litigation against the government-authorized drug pricing reduction ordered due to the reimbursement listing of biosimilar. Lilly argued Daewon Pharmaceutical’s biosimilar Terosa cannot be considered equivalent to its original drug, the court rejected the argument. Accordingly, the up
- Policy
- GC Pharma begins clinical trial for new type of Fenofibrate
- by Lee, Tak-Sun Aug 11, 2020 06:03am
- In the triglyceride treatment market, GC Pharma, which is running on top of the Fenofibrate 'Lipidil supra', has begun clinical trials for a new formulation of the same ingredient. It seems to be an attempt to improve the shortcomings of Lipidil supra, which should be taken after meals. The MFDS approved a phase I clinical trial protocol to e
- Policy
- The HIRA deliberated on benefits for Rinvoq & Kisqali
- by Kim, Jung-Ju Aug 11, 2020 06:02am
- The HIRA (Director Sun-min Kim) deliberated on the adequacy of benefits for these two new drugs at the Pharmaceutical Benefits Advisory Committee held on the 6th and concluded that AbbVie Korea's new drug for rheumatoid arthritis 'Rinvoq ER 15mg (Upadacitinib)' was to be eligible for reimbursement, and Novartis’ advanced or metastatic breast
- Policy
- Ongentys and Rekovelle soon to receive healthcare benefit
- by Kim, Jung-Ju Aug 11, 2020 06:02am
- The South Korean health authority is readying for healthcare reimbursement listing on SK Chemical’s new Parkinson’s disease treatment Ongentys (opicapone) capsule and Ferring Korea’s assisted reproduction techniques (ART) add-on Rekovelle (follitropin delta) prefilled pen as they have reached an agreement on their negotiations. During
- Company
- Appropriate use of NOAC in patient with major bleeding risk
- by Eo, Yun-Ho Aug 10, 2020 06:02am
- As the prescription cases of new oral anti-coagulant (NOAC) have been accumulating, the prescribers are paying a closer attention on adequately prescribing for patients with high risk of bleeding. HAS-BLED score, the most well known scoring system for measuring major bleeding risk, indicates patients scoring over three are equivalent to
- Policy
- Benefits for combination therapy with DM can be expanded
- by Lee, Tak-Sun Aug 10, 2020 06:01am
- Combination therapy between diabetes treatment drugs that are not currently approved for efficacy and effectiveness can also receive benefits. As the MFDS simplifies the method of describing the efficacy and effect of type II DM combination therapy, the insurance authorities can apply benefits to the existing off-label combination therapy (us
- Company
- Hanmi, promotes COVID-19 tx, Ambroxol HCl Sln for Inhalation
- by Aug 10, 2020 06:00am
- Hanmi's Chinese subsidiary, Beijing Hanmi Pharmaceutical, announced on the 6th that it will develop a secretolytic agent, 'Ambroxol HCl Solution for Inhalation' as COVID-19 treatment. Earlier, top expert consensus in Chinese pediatrics and two organizations at the drug management control center in Guangdong Province, China, commented on
